BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38277372)

  • 1. Carbapenem-resistant Klebsiella pneumoniae bloodstream infections in haematological malignances and hematopoietic stem cell transplantation: Clinical impact of combination therapy in a 10-year Brazilian cohort.
    de Souza ILA; Cappellano P; Ferreira DB; Bergamasco MD; das Chagas Neto TC; Kerbauy FR; Baiocchi OCG; Pignatari ACC
    PLoS One; 2024; 19(1):e0297161. PubMed ID: 38277372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colistin versus polymyxin B for the treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infections.
    Vieceli T; Henrique LR; Rech TH; Zavascki AP
    J Infect Chemother; 2024 Jul; 30(7):621-625. PubMed ID: 38244722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbapenem-resistant Klebsiella pneumoniae in high-risk haematological patients: factors favouring spread, risk factors and outcome of carbapenem-resistant Klebsiella pneumoniae bacteremias.
    Micozzi A; Gentile G; Minotti C; Cartoni C; Capria S; Ballarò D; Santilli S; Pacetti E; Grammatico S; Bucaneve G; Foà R
    BMC Infect Dis; 2017 Mar; 17(1):203. PubMed ID: 28283020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors and mortality of carbapenem-resistant Klebsiella pneumoniae bloodstream infection in a tertiary-care hospital in China: an eight-year retrospective study.
    Chen J; Ma H; Huang X; Cui Y; Peng W; Zhu F; Ma S; Rao M; Zhang P; Yang H; Su L; Niu R; Pan P
    Antimicrob Resist Infect Control; 2022 Dec; 11(1):161. PubMed ID: 36536423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for carbapenem-resistant K. pneumoniae bloodstream infection and predictors of mortality in Chinese paediatric patients.
    Zhang Y; Guo LY; Song WQ; Wang Y; Dong F; Liu G
    BMC Infect Dis; 2018 May; 18(1):248. PubMed ID: 29855274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors and mortality for patients with Bloodstream infections of Klebsiella pneumoniae during 2014-2018: Clinical impact of carbapenem resistance in a large tertiary hospital of China.
    Chang H; Wei J; Zhou W; Yan X; Cao X; Zuo L; Chen S; Yao K; Huang R; Chen Y; Wu C
    J Infect Public Health; 2020 May; 13(5):784-790. PubMed ID: 31843651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey.
    Trecarichi EM; Pagano L; Martino B; Candoni A; Di Blasi R; Nadali G; Fianchi L; Delia M; Sica S; Perriello V; Busca A; Aversa F; Fanci R; Melillo L; Lessi F; Del Principe MI; Cattaneo C; Tumbarello M;
    Am J Hematol; 2016 Nov; 91(11):1076-1081. PubMed ID: 27428072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for treatment failure of polymyxin B monotherapy for carbapenem-resistant Klebsiella pneumoniae infections.
    Dubrovskaya Y; Chen TY; Scipione MR; Esaian D; Phillips MS; Papadopoulos J; Mehta SA
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5394-7. PubMed ID: 23959321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy with polymyxin B for carbapenemase-producing Klebsiella pneumoniae bloodstream infection.
    Medeiros GS; Rigatto MH; Falci DR; Zavascki AP
    Int J Antimicrob Agents; 2019 Feb; 53(2):152-157. PubMed ID: 30722960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology of carbapenem-resistant
    Wang Y; Lei H; Zhang Y; Yang Q; Wang Y; Wang J; Xu C; Yu J; Zhou L; Kang X; Cui L
    Antimicrob Resist Infect Control; 2018; 7():66. PubMed ID: 29942492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Epidemiology and Risk Factors of Carbapenem-Resistant Klebsiella Pneumoniae Bloodstream Infections in Wuhan, China.
    Liu C; Liu L; Jin MM; Hu YB; Cai X; Wan L; Zhang HY; Li RY; Wu XJ
    Curr Med Sci; 2022 Feb; 42(1):68-76. PubMed ID: 34985611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors and mortality for elderly patients with bloodstream infection of carbapenem resistance Klebsiella pneumoniae: a 10-year longitudinal study.
    Chen Y; Chen Y; Liu P; Guo P; Wu Z; Peng Y; Deng J; Kong Y; Cui Y; Liao K; Huang B
    BMC Geriatr; 2022 Jul; 22(1):573. PubMed ID: 35831805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial treatment of monomicrobial phenotypic carbapenem-resistant Klebsiella pneumoniae bacteremia: Two are better than one.
    Tsai WC; Syue LS; Ko WC; Lo CL; Lee NY
    J Microbiol Immunol Infect; 2022 Dec; 55(6 Pt 2):1219-1228. PubMed ID: 34635426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Retrospective Analysis of Risk Factors and Outcomes of Carbapenem-Resistant Klebsiella pneumoniae Bacteremia in Nontransplant Patients.
    Xiao T; Zhu Y; Zhang S; Wang Y; Shen P; Zhou Y; Yu X; Xiao Y
    J Infect Dis; 2020 Mar; 221(Suppl 2):S174-S183. PubMed ID: 32176799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical impact of cefepime breakpoint in patients with carbapenem-resistant Klebsiella pneumoniae bacteraemia.
    Lee NY; Lo CL; Chen PL; Syue LS; Li CW; Li MC; Ko WC
    Int J Antimicrob Agents; 2021 Feb; 57(2):106250. PubMed ID: 33264671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection.
    Giannella M; Trecarichi EM; Giacobbe DR; De Rosa FG; Bassetti M; Bartoloni A; Bartoletti M; Losito AR; Del Bono V; Corcione S; Tedeschi S; Raffaelli F; Saffioti C; Spanu T; Rossolini GM; Marchese A; Ambretti S; Cauda R; Viscoli C; Lewis RE; Viale P; Tumbarello M;
    Int J Antimicrob Agents; 2018 Feb; 51(2):244-248. PubMed ID: 28842283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bloodstream infections among carriers of carbapenem-resistant Klebsiella pneumoniae: etiology, incidence and predictors.
    Amit S; Mishali H; Kotlovsky T; Schwaber MJ; Carmeli Y
    Clin Microbiol Infect; 2015 Jan; 21(1):30-4. PubMed ID: 25636924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors and clinical outcomes of carbapenem-resistant Klebsiella pneumoniae bacteraemia in children: a retrospective study.
    Meng H; Yang J; Niu M; Zhu H; Zhou Y; Lu J
    Int J Antimicrob Agents; 2023 Oct; 62(4):106933. PubMed ID: 37500022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective observational cohort study of the clinical epidemiology of bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae in an OXA-48 endemic setting.
    Aslan AT; Kırbaş E; Sancak B; Tanrıverdi ES; Otlu B; Gürsoy NC; Yılmaz YA; Tozluyurt A; Liste Ü; Bıçakcıgil A; Hazırolan G; Dağ O; Güven GS; Akova M;
    Int J Antimicrob Agents; 2022 Apr; 59(4):106554. PubMed ID: 35176476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and Molecular Characterizations of Carbapenem-Resistant Klebsiella pneumoniae Causing Bloodstream Infection in a Chinese Hospital.
    Zhang N; Qi L; Liu X; Jin M; Jin Y; Yang X; Chen J; Qin S; Liu F; Tang Y; Jia R; Zhang X; Wang Y; Guo J; Liu J; Wang C; Chen Y
    Microbiol Spectr; 2022 Oct; 10(5):e0169022. PubMed ID: 36190403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.